Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Disappointing news from DIAN-TU
March 2020
SHARING OPTIONS:

ST. LOUIS—Top-line results from the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), a Phase 3 trial testing solanezumab and gantenerumab in individuals with a rare inherited form of Alzheimer’s disease, showed that both drugs fell short of the primary endpoint of slowing cognitive decline. The study, led by Washington University School of Medicine in St. Louis researchers, also collected blood samples, spinal fluid samples and brain scans in hopes of better identifying Alzheimer’s disease biomarkers.
 
“While we are disappointed that patients in this study did not see a benefit, we need to keep in mind that Alzheimer’s is a complicated disease due to complex, multifactorial causes,” commented Dr. Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation. “Every well-designed trial, such as DIAN-TU, adds to our scientific knowledge and informs future research toward our ultimate goal of having effective treatments for people with Alzheimer’s.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.